to that, Ms. Fanucci served as Senior Vice President, Chief Financial Officer of Millennium Pharmaceuticals, Inc., or Millennium, a biopharmaceutical company that was subsequently acquired
by Takeda Pharmaceuticals, from July 2004 to January 2009. While at Millennium, she also served as Senior Vice President, Finance and Corporate Strategy from October 2003 to July 2004, Vice President, Finance and Corporate Strategy from July 2003 to
October 2003 and Vice President, Corporate Development and Strategy from July 2000 to July 2003. Prior to Millennium, she was Vice President of Corporate Development and Strategy at Genzyme Corporation, a biotechnology company, from
1998 to 2000. Ms. Fanucci serves on the board of directors of multiple public companies, including as chair of the board of directors of Cyclerion Therapeutics, Inc. and director of Alnylam Pharmaceuticals, Inc. and Syros Pharmaceuticals, Inc.
Ms. Fanucci formerly served as a director of publicly traded companies Ironwood Pharmaceuticals, Inc. and Momenta Pharmaceuticals, Inc. Ms. Fanucci holds a B.S. in pharmacy from West Virginia University and her M.B.A. from Northeastern
University. We believe that Ms. Fanucci is qualified to serve on our board of directors due to her expertise with public and financial accounting matters and her experience leading financial organizations in biotechnology companies.
Peter Kolchinsky, Ph.D. Dr. Kolchinsky has been a member of our board of directors since December 2019. He is a founder and Managing
Partner at RA Capital Management, L.P., or RA Capital. Dr. Kolchinsky is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. Dr. Kolchinsky has served as a member
of the board of directors of various private and publicly traded companies, including Synthorx, Inc. from May 2018 to January 2020, Dicerna Pharmaceuticals, Inc. from July 2013 to December 2019, and G1 Therapeutics, Inc. from February 2015 to May
2017, and currently serves on the board of directors of WAVE Life Sciences, Ltd., Icosavax, Inc. and Research Alliance Corp. II, where he serves as chairman and Chief Executive Officer. He also leads the RA Capitals engagement and publishing
efforts, which aim to make a positive social impact and spark collaboration among healthcare stakeholders, including patients, physicians, researchers, policymakers, and industry. He served on the Board of Global Science and Technology for the
National Academy of Sciences, authored The Great American Drug Deal and The Entrepreneurs Guide to a Biotech Startup, and frequently writes and speaks on the future of biotechnology innovation. Dr. Kolchinsky holds
a B.A. from Cornell University and a Ph.D. in Virology from Harvard University. We believe that Dr. Kolchinsky is qualified to serve on our board of directors due to his experience as a venture capitalist and his experience serving on the
boards of various healthcare and life science companies.
Thomas G. Wiggans. Mr. Wiggans has been a member of our board of directors
since September 2020. Since March 2022, Mr. Wiggans has been the Chief Executive Officer and a member of the board of directors of Pardes Biosciences, Inc., a publicly traded biopharmaceutical company. Prior to that, Mr. Wiggans founded
Dermira, Inc., or Dermira, a publicly held pharmaceutical company, in August 2010 and served as its Chief Executive Officer from September 2010 and on its board of directors from October 2014 until Dermira was acquired by Eli Lilly and Company, or
Eli Lilly, in February 2020. From October 2007, Mr. Wiggans served as chairman of the board of directors of Peplin, Inc., or Peplin, and in July 2007, he became its Chief Executive Officer, and he served in these positions until
Peplins acquisition by LEO Pharma A/S in November 2009. Previously, Mr. Wiggans served as Chief Executive Officer of Connetics Corporation, or Connetics, from July 1994, and as chairman of the board of directors of Connetics from January
2006, and he served in these positions until December 2006 when Connetics was acquired by Stiefel Laboratories, Inc. From 1992 to 1994, Mr. Wiggans served as President and Chief Operating Officer of CytoTherapeutics Inc. From 1980 to 1992,
Mr. Wiggans served at Ares-Serono S.A. in various management positions including President of its U.S. pharmaceutical operations and Managing Director of its U.K. pharmaceutical operations. Mr. Wiggans began his career with Eli Lilly.
Mr. Wiggans has been a member of the boards of directors of Annexon, Inc. since February 2017 and CymaBay Therapeutics, Inc. since April 2021. Mr. Wiggans also served on the boards of directors of various industry organizations,
educational institutions and private and public companies, including Onyx Pharmaceuticals, Inc. Sangamo Biosciences, Inc. and Somaxon Pharmaceuticals, Inc., and is a member of the board of directors of the Biotechnology Innovation Organization and
the board of trustees of the University of Kansas Endowment Association. Mr. Wiggans holds a B.S. in pharmacy from the University of Kansas and an M.B.A. from Southern Methodist University. We believe that Mr. Wiggans depth of senior
management
12